(5alpha,17beta)-17-Hydroxy-androstan-3-one
Stanolone
CAS: 521-18-6
Molecular Formula: C19H30O2
(5alpha,17beta)-17-Hydroxy-androstan-3-one - Names and Identifiers
| Name | Stanolone |
| Synonyms | Stanolone 5A-Androstan-3-on-17B-ol 17-Hydroxyandrostan-3-one 17beta-Hydroxy-3-androstanone (17beta)-17-hydroxyandrostan-3-one 5a-Androstan-3-one, 17beta-hydroxy- 17-beta-hydroxy-5-alpha-androstan-3-on (3alpha,5alpha)-3-hydroxyandrostan-17-one 5α-androstan-17β-ol-3-one solution,100ppm (5alpha,17beta)-17-Hydroxy-androstan-3-one (17beta)-3-oxoandrost-4-en-17-yl propanoate (5-alpha,17-beta)-17-hydroxyandrostan-3-one 17-hydroxy-,(5-alpha,17-beta)-androstan-3-on -(5-alpha,17-beta)-17-hydroxyandrostan-3-one (5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (8R,9S,10S,13S,14S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one |
| CAS | 521-18-6 |
| EINECS | 208-307-3 |
| InChI | InChI=1/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12?,14-,15-,16-,17-,18-,19-/m0/s1 |
| InChIKey | NVKAWKQGWWIWPM-ABEVXSGRSA-N |
(5alpha,17beta)-17-Hydroxy-androstan-3-one - Physico-chemical Properties
| Molecular Formula | C19H30O2 |
| Molar Mass | 290.45 |
| Density | 1.0320 (rough estimate) |
| Melting Point | 178-183°C |
| Boling Point | 372.52°C (rough estimate) |
| Specific Rotation(α) | 27 º |
| Flash Point | 9℃ |
| Water Solubility | 344.3g/L(temperature not stated) |
| Vapor Presure | 1.5E-08mmHg at 25°C |
| Appearance | neat |
| Merck | 13,8872 |
| BRN | 2056371 |
| pKa | 15.08±0.60(Predicted) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.4709 (estimate) |
| Use | Androgens |
| In vitro study | In androgen receptor-positive bladder cancer cells UMUC3 and TCC-SUP, dihydrotestosterone (DHT) increases the expression of EGFR and ERBB2 at the mRNA and protein levels. In AR-positive cells, DHT also upregulated the phosphorylation level of EGFR and its downstream proteins AKT(pAKT) and ERK1/2(pERK). |
| In vivo study | DHT reduced muscle atrophy symptoms and increased body weight in SOD1-G93A mice. DHT treatment increased insulin-like growth factor -1 expression in muscle, exerting its muscular trophic and neurotrophic effects through retrograde axoplasmic transport. Its treatment also slows the denervation at the neuromuscular junction and reduces the loss of axons and motor neurons. The DHT-treated SOD1-G93A mice had improved motor behavior and a longer life span. |
(5alpha,17beta)-17-Hydroxy-androstan-3-one - Risk and Safety
| Risk Codes | R61 - May cause harm to the unborn child R40 - Limited evidence of a carcinogenic effect R39/23/24/25 - R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R11 - Highly Flammable |
| Safety Description | S53 - Avoid exposure - obtain special instructions before use. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37 - Wear suitable protective clothing and gloves. S16 - Keep away from sources of ignition. |
| UN IDs | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| RTECS | BV8052000 |
